Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
105 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Recruiting A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)
Condition: Hemophilia A
Intervention: Drug: Emicizumab
22 Not yet recruiting A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
23 Recruiting Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Wilate
24 Recruiting Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Intervention: Biological: OBIZUR
25 Recruiting Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human cl rhFVIII
26 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
27 Recruiting Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition: Hemophilia A, Congenital
Intervention: Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
28 Recruiting Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions: Hemophilia A;   Factor VIII
Intervention: Drug: Recombinant VIII factor
29 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
30 Not yet recruiting Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
Conditions: Hemophilia A;   Hemophilia;   Factor VIII Deficiency
Intervention: Drug: Octocog Alfa
31 Not yet recruiting Improved Factor VIII Inhibitor Evaluation
Conditions: Hemophilia;   Hemophilia A
Intervention:
32 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
33 Recruiting A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions: Haemophilia A;   Haemophilia B
Interventions: Drug: ELOCTA;   Drug: ALPROLIX
34 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
35 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
36 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
37 Recruiting Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
Condition: Hemophilia A
Interventions: Drug: efmoroctocog alfa;   Drug: Factor VIII
38 Recruiting Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
Condition: Hemophilia A
Intervention:
39 Recruiting BAX 802 in CHA With Inhibitors
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
40 Recruiting BAX 855 Previously Untreated Patient (PUP)
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.